Final results of the TANIA randomized phase III trial of bevacizumab (BEV) after progression on 1st-line BEV therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

被引：0

作者：

Vrdoljak, E.

Marschner, N.

Zielinski, C.

Gligorov, J.

Cortes, J.

Puglisi, F.

Aapro, M.

Fallowfield, L.

Fontana, A.

Inbar, M.

Kahan, Z.

Welt, A.

Levy, C.

Brain, E.

Pivot, X.

Putzu, C.

Gonzalez-Martin, A.

Ebel, K.

Easton, V.

von Minckwitz, G.

机构：

[1] Ctr Oncol, Split, Croatia

[2] Outpatient Canc Ctr, Freiburg, Germany

[3] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria

[4] CECOG, Vienna, Austria

[5] Hop Tenon, F-75970 Paris, France

[6] Vall dHebron Univ Hosp, Barcelona, Spain

[7] Univ Hosp Udine, Udine, Italy

[8] Clin Genolier, Inst Multidisciplinaire Oncol, Genolier, Switzerland

[9] Univ Sussex, Brighton & Sussex Med Sch, SHORE C, Falmer, England

[10] Univ Hosp Pisa, Ist Toscana Tumori, Pisa, Italy

[11] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel

[12] Univ Szeged, Szeged, Hungary

[13] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Essen, Germany

[14] Ctr Francois Baclesse, F-14021 Caen, France

[15] Hop Rene Huguenin, Inst Curie, St Cloud, France

[16] Univ Hosp Jean Minjoz, Besancon, France

[17] Univ Hosp Sassari, Sassari, Italy

[18] MD Anderson Canc Ctr, Madrid, Spain

[19] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland

[20] Stamford Consultants AG, Basel, Switzerland

[21] German Breast Grp, Neu Isenburg, Germany

[22] Univ Womens Hosp, Frankfurt, Germany

来源：

CANCER RESEARCH | 2016年 / 76卷

关键词：

D O I：

10.1158/1538-7445.SABCS15-P6-14-01

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P6-14-01

引用

页数：2

共 50 条

[31] Hand-foot-syndrome (HFS) is a strong predictor for OS and PFS in HER2-negative metastatic breast cancer (mBC) treated with first-line capecitabine (CAP) plus bevacizumab (BEV): Results of a subanalysis of the randomized phase III CECOG TURANDOT trial
Christoph, Zielinski C.
Istvan, Lang
Semir, Beslija
Zsuzsanna, Kahan
Inbar, Moshe J.
Salomon, Stemmer M.
Rodica, Anghel
Damir, Vrbanec
Diethelm, Messinger
Thomas, Brodowicz
CANCER RESEARCH, 2015, 75
[32] Abrogation of resistance against bevacizumab (Bev) by mitochondrial inhibition: A phase 0 randomized trial of Bev plus ME344 or placebo in early HER2-negative breast cancer (HERNEBC).
Quintela-Fandino, Miguel
Apala, Juan V.
Salgado, Alfonso Cortes
Mouron, Silvana Andrea
Guerra, Juan Antonio
Cortes, Mana Gion
Morente, Manuel
Manso, Luis
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[33] Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)
Dieras, V.
Glaspy, J.
Brufsky, A.
Bondarenko, I.
Lipatov, O.
Perez, E. A.
Chan, S.
Zhou, X.
Phan, S. C.
Robert, N.
EJC SUPPLEMENTS, 2009, 7 (02): : 265 - 265
[34] RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)
Robert, N. J.
Dieras, V.
Glaspy, J.
Brufsky, A.
Bondarenko, I.
Lipatov, O.
Perez, E.
Yardley, D.
Zhou, X.
Phan, S.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[35] Efficacy and safety of first-line bevacizumab (Bev) combined with paclitaxel (Pac): An observational study in 786 patients (pts) with HER2-negative metastatic breast cancer (mBC).
Klare, P.
Foerster, F. G.
Geberth, M.
Schneeweiss, A.
Tesch, H.
Kuemmel, S.
Schumacher, C.
Hollburg, W.
Soeling, U.
Schmidt, M.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[36] PFS by patient subgroup for standard chemotherapies in combination with bevacizumab (BV) in the first-line treatment of HER2-negative locally recurrent (LR) or metastatic breast cancer (mBC): results from RIBBON-1
Bondarenko, I.
Glaspy, J.
Brufsky, A.
Lipatov, O.
Perez, E. A.
Chan, S.
Zou, X.
Phan, S. C.
Robert, N. J.
Dieras, V.
EJC SUPPLEMENTS, 2010, 8 (03): : 198 - 198
[37] Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: Maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast can
Doval, Dinesh
Cinieri, Saverio
Bozcuk, Hakan
Pierga, Jean-Yves
Altundag, Kadri
Wang, Xiaojia
Gupta, Sudeep
Lopez Vivanco, Guillermo
Gupta, Vineet
Chmielowska, Ewa
Bines, Jose
Montcuquet, Philippe
Namour, Alfred
Alba, Emilio
Mustacchi, Giorgio
Cortes, Paulo
de Ducla, Sabine
Freudensprung, Ulrich
Fallowfield, Lesley
Gligorov, Joseph
CANCER RESEARCH, 2015, 75
[38] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
Salvador, J.
Manso, L.
de la Haba, J.
Jaen, A.
Ciruelos, E.
de Villena, M. C.
Gil, M.
Murias, A.
Galan, A.
Jara, C.
Bayo, J.
Baena, J. M.
Casal, J.
Mel, J. R.
Blancas, I.
Sanchez Rvira, P.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (02): : 160 - 166
[39] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
J. Salvador
L. Manso
J. de la Haba
A. Jaen
E. Ciruelos
M. C. de Villena
M. Gil
A. Murias
A. Galan
C. Jara
J. Bayo
J. M. Baena
J. Casal
J. R. Mel
I. Blancas
P. Sanchez Rvira
Clinical and Translational Oncology, 2015, 17 : 160 - 166
[40] FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial
Loupakis, Fotios
Cremolini, Chiara
Masi, Gianluca
Lonardi, Sara
Zagonel, Vittorina
Trenta, Patrizia
Tomasello, Gianluca
Ronzoni, Monica
Ciuffreda, Libero
Zaniboni, Alberto
Tonini, Giuseppe
Buonadonna, Angela
Valsuani, Chiara
Chiara, Silvana
Carlomagno, Chiara
Boni, Corrado
Marcucci, Lorenzo
Boni, Luca
Falcone, Alfredo
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)

← 1 2 3 4 5 →